Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer by licensing an early-stage candidate from Kumquat Biosciences. The deal – which has a total value of up to ...

Bayer's chief executive Bill Anderson looks set to keep his role until nearly the decade, as his turnaround plan for the group starts to deliver results. Just over two years into Anderson's tenure, ...

Seven years ago, two events set forth a domino effect culminating in Bayer leaders having a potential “tough decision” of whether or not the company will continue to manufacture its legacy herbicide ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s crop science division. What has them bullish? First, Bayer is optimistic the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...